No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Apex Biotechnology Corp. is a Taiwanese firm that specializes in the global development, manufacturing, and distribution of medical devices designed for home use, all powered by sophisticated biosensor technology. Their comprehensive product lineup features a variety of personal health monitoring systems, including those for tracking blood glucose, uric acid, hemoglobin, cholesterol, lactate, HbA1c, and ketone levels. In addition, the company provides self-testing solutions for coagulation and multi-parameter analysis, alongside advanced hemoglobin screening systems. Beyond patient diagnostics, Apex Biotech also offers systems for detecting pesticide residues. The company further extends its services to include digital care management and telehealth platforms. Established in 1997, Apex Biotechnology Corp. operates from its headquarters located in Hsinchu City, Taiwan.
www.apexbio.comNo one on the platform currently holds 1733.TW.
No tracked institution reports a position in 1733.TW as of their last filing.
No one on the platform has traded 1733.TW yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 8.3% | 9.5% | 7.7% | — | — | — |
| Rev. Growth % | 5.0% | -0.6% | ||||
| Profit Margin % | 8.4% | 8.0% | 5.9% | |||
| Free Cash Flow Margin % | 7.7% | 8.5% | 8.9% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $12.5B | +8.3% | $7.39 | $7.39–$7.39 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 6 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-07 | $0.50 | $0.37 | -26.0% |
| 2026-03-13 | $1.73 | $0.50 | -71.1% |
| 2025-08-08 | $0.50 | $0.29 | -42.0% |
| 2025-03-18 | $0.50 | $0.62 | +24.0% |
| 2025-02-25 | $0.50 | $0.38 | -23.2% |
| 2024-11-13 | $0.20 | $0.33 | +65.0% |
| $29.10 |
| +2.46% |
| $2.0B |
| — |
| 6634.TWOSinew Pharma Inc. | $59.00 | +5.55% | $4.2B | — |
| 6808.TWO3D Global Biotech Inc. | $30.80 | +1.48% | $2.4B | — |
Source: Financial Modeling Prep · peers by sector/industry